Investigational immunotherapy drug well tolerated in those with rare form of melanoma
Monday, June 6, 2016 - 11:31
in Health & Medicine
An investigational immunotherapy drug being tested in the treatment of a rare form of skin cancer known as Merkel cell carcinoma has been found to be well tolerated with a clinical benefit seen in up to 42 percent of patients who failed prior treatment and were observed for at least six months.